Don't miss the next Capital Cell Afterwork on Rare Diseases & Orphan Drugs

Sign up and join the next Capital Cell Afterwork in partnership with Voisin Consulting Life Sciences (VCLS), where they'll dive into the latest insights on Rare Diseases & Orphan Drugs and showcase some of the most promising investment opportunities in this sector.

• Date: May 22nd
• Location: Paris (Hybrid format)
• Time: 18 hrs 

The panel will feature top experts, offering diverse perspectives – from patient advocates to founders and pharma leaders. Together, they’ll discuss why rare diseases are capturing investors' attention, the vital role of patient associations, emerging trends, and the significant market potential in saving lives.

Meet the panelists:

• Dr. Emmanuelle M. Voisin, Founder & CEO, Voisin Consulting Life Sciences (VCLS)
• Yann Godfrin, Ph.D., CEO, Axoltis Pharma
• Sabine Turgeman, CEO, ARSLA (the French ALS patient association)
• Alexandre Lemoalle, President, Ampleia & Managing Partner, Finpact
• Julien Gillet-Daubin, Director of Capital Cell France, will moderate the session.

Register to attend in person with Eventbrite (limited tickets available), or join online via Zoom registration.